• Antibody-drug conjugates
• Targeting platform – 'OptiLink'
• Light activated cancer therapy – 'ProstaLite'
• MRI contrast agents & imaging
• Photosensitiser innovations
• Additional products and applications

• Investment History & Strategy
• Partnering opportunities

• Press Releases
• News Items
• Scientific Publications

• Background
• Achievements
• The Team
• Sitemap

PhotoBiotics Background

PhotoBiotics Ltd was spun out from Imperial College London because of a recognised need to improve on the current light-activated cancer treatment, known as photodynamic therapy or PDT.

PhotoBiotics brought together the disciplines of chemistry, photophysics and biochemistry to find a way to target the PDT to the tumour, thus enhancing the efficacy of cancer treatment and also reducing systemic ambient light sensitivity post-treatment (i.e. painful sunburn-like symptoms).

PhotoBiotics' R&D team has succeeded in its primary objective of developing a technology platform to address the needs of PDT, and is now exemplifying how this platform, denoted OptiLink, has utility across a wide range of other applications, in particular, MRI contrast agents and imaging and others.

OptiLink is a unique and simple conjugation platform which enables multiple attachment of drugs to antibody fragments. Counter-intuitively, OptiLink allows far higher drug loadings on scFvs than has ever been achieved with whole monoclonal antibodies.